Several seemingly minor safety issues could complicate the labeling discussions for Horizon Therapeutics PLC's teprotumumab, proposed for active thyroid eye disease (TED), a rare condition.
US Food and Drug Administration assessors did not indicate any of the adverse events mentioned could prevent or delay approval....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?